www.dailypolitical.com ·
Ubs Group Ag Cuts Position in Celldex Therapeutics Inc Cldx
Topic context
This topic has been covered 420725 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThis is a routine institutional portfolio rebalancing with no direct commercial mechanism for Celldex's operations or the biotech sector. The stake reduction by UBS is a single fund manager's decision, not indicative of a sector-wide trend. No product, supply chain, or margin impact is identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- UBS Group AG reduced its stake in Celldex Therapeutics by 21.6% in Q4, selling 89,985 shares valued at ~$8.87 million.
- Celldex reported a quarterly loss of $1.18 per share on May 7, 2026, missing estimates, with revenue of $0.02 million.
- Stock opened at $31.34, 12-month range $18.55-$35.79, market cap $2.46 billion.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
finance.yahoo.com
Biosig Technologies Q1 Earnings Call
zerohedge.com